Nouscom is a cancer vaccine company with a particular focus on off-the-shelf vaccines. It’s lead product, Nous209, is in phase II for patients with metastatic colorectal cancer (mCRC) whose tumours have high microsatellite instability (hMSI). Nouscom also has a collaboration with JnJ, and recently announced that Janssen has received US IND acceptance for VAC85135, for an oncology indication.